By Stephen Nakrosis 
 

Regeneron Pharmaceuticals Inc. and Sanofi said Thursday a U.S. Phase 3 trial of Kevzara in Covid-19 patients didn't meet primary or key secondary endpoints.

The companies said the trial studied Kevzara, or sarilumab, in Covid-19 patients requiring mechanical ventilation. Results showed the trial "did not meet its primary and key secondary endpoints when Kevzara was added to best supportive care compared to best supportive care alone."

The companies also said the "primary analysis group included 194 patients who were critically ill with Covid-19 and were receiving mechanical ventilation at the time of enrollment."

Based on the results, the companies said, the trial has been stopped. Results will be submitted to a peer-reviewed publication later this year, they added.

 

--Write to Stephen Nakrosis at stephen.nakrosis@wsj.com

 

(END) Dow Jones Newswires

July 02, 2020 17:07 ET (21:07 GMT)

Copyright (c) 2020 Dow Jones & Company, Inc.
Sanofi (EU:SAN)
Historical Stock Chart
From Feb 2024 to Mar 2024 Click Here for more Sanofi Charts.
Sanofi (EU:SAN)
Historical Stock Chart
From Mar 2023 to Mar 2024 Click Here for more Sanofi Charts.